NIVABUPA Niva Bupa Health Insurance Company Q4 FY25 results (Jan–Mar 2025) and concall
Niva Bupa Health reported a strong performance for FY25, marked by robust 32% GWP growth on a comparable basis and a 91% surge in IFRS PAT. The company demonstrated significant operational leverage, with its like-to-like combined ratio improving by 270 basis points to 96.1%, driven by enhancements in both loss and expense ratios. Management highlighted strategic progress in expanding its distribution network, launching new products like 'Rise' for the mass market, and effectively managing claim inflation at 5%, which is below general industry perceptions. The company maintains a strong capital
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 1,321 | 1,258 | 1,671 |
| EBITDA | -66 | -24 | 251 |
| Net profit | 13 | 13 | 206 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
